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id They Lower
tress in the Trial?
r Was It Just Wasted Energy?*
tephen P. Sanders, MD, FACC
ome, Italy
n this issue of the Journal, Duboc et al. (1) report the results
f a multicenter clinical trial of perindopril, an angiotensin-
onverting enzyme (ACE) inhibitor, for the prevention of
eft ventricular dysfunction in young patients with Du-
henne muscular dystrophy. The investigators showed pos-
tive benefit from this treatment after five years, with fewer
atients in the treatment group exhibiting left ventricular
ysfunction (ejection fraction 45%). At first glance this
rial might not seem so important or the result particularly
urprising, but it should be of real interest to pediatric
ardiologists for two reasons. First, as one of an increasing
umber of clinical trials being performed in children, it
llustrates many of the difficulties encountered in this
opulation and the need for patience and perseverance on
he part of investigators. Second, it adds another small piece
o the puzzle regarding the role of cytoskeletal proteins in
eart failure.
See page 855
Until recently, few clinical trials had been performed in
hildren with heart disease (2). In fact, before the year 2000
nly about 20 randomized, controlled trials had been
ublished in pediatric cardiovascular medicine (3). The last
ew years have seen clinical trials being performed in
hildren in increasing numbers because of: 1) individual
nvestigator initiative, as in this case; 2) programs sponsored
y the National Institutes of Health (4); and 3) incentives
rovided to industry by the Food and Drug Administration
odernization Act and, subsequently, the Best Pharmaceu-
icals for Children Act (5). Although progress is being made
hanks to these important initiatives, still most drugs used in
hildren have not been tested adequately to understand the
ppropriate dose, the efficacy, and the safety.
This perindopril trial highlights some of the problems
eing faced by pediatric investigators. The 80 subjects
creened for this trial represent 10 major hospitals in France
aring for children with muscle disease. Of these, 57
ubjects met entry criteria for the trial. Compared to most
ardiovascular trials in adults, these are very small numbers,
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.i
From the Dipartimento Medico Chirurgico di Cardiologia Pediatrica, Ospedale
ediatrico Bambino Gesù, Rome, Italy.arely enough to provide adequate statistical power. Fortu-
ately for our species, but unfortunately for investigators,
ardiovascular disease is rare in children. Networks such as
he French Working Group of Heart Involvement in
yopathies, which carried out this trial, are indispensable
or conducting clinical trials in children. No single center, or
ven small group of centers, has enough patients with these
are diseases to perform meaningful trials.
In addition to small numbers of patients, the time course
eeded to achieve clinically meaningful end points is often
ong. No difference in ventricular function was evident
etween treatment and placebo groups after the initial
hree-year, blinded, randomized Phase 1. Only after an
dditional two years of open-label treatment in Phase 2 was
difference detected. Even after five years, the only end
oint realized was a surrogate, ventricular function. An
dditional year of observation has shown a non-significant
rend toward reduced mortality in the treatment group. One
opes the investigators will continue to persevere in follow-
ng these patients in anticipation of demonstrating a mor-
ality benefit. Even more importantly, it is essential that
unding agencies understand the cost and the time needed
o perform meaningful trials in children and build this into
heir evaluation of clinical research proposals.
The story of dystrophin and other cytoskeletal and
xtracellular matrix proteins in heart failure is an interesting,
nd somewhat unexpected, one (6). This molecular chain
ppears to connect the contractile apparatus within the
yocyte with the extracellular structure of the muscle for
orce transduction across the sarcolemma. Components of
he chain stabilize the sarcolemma during contraction and
orce transmission. Absence or certain mutations of com-
onents of the chain (dystrophin in Duchenne muscular
ystrophy) appear to increase the likelihood of rupture of
he sarcolemma during contraction, with cell death and
brous replacement. The clinical correlates of this are the
keletal muscle atrophy and weakness that develop during
hildhood in Duchenne patients and the cardiomyopathy
hat appears usually in the second decade. In an experimen-
al model of dystrophin deficiency, the extent of sarcolem-
al damage was directly related to the mechanical stress
laced on the muscle (7). Hence the hypothesis that led to
his clinical trial of perindopril: reduction of left ventricular
fterload (wall stress) should decrease the rate and extent of
amage to the myocardium produced by contractions in the
bsence of dystrophin. The data presented by Duboc et al.
1) support this hypothesis. Their Figure 1 shows clear
ivergence in left ventricular function between the group
reated for five years and that treated for two years with an
CE inhibitor. However, both groups exhibit significant
eductions in function, suggesting that this treatment only
educes the rate of progression and does not completely
revent deterioration. The authors suggest beginning all
hildren with Duchenne muscular dystrophy on ACE
nhibitor therapy as early as nine years (the youngest
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March 15, 2005:858–9 Editorial Commentatients in their study population). The apparent cumulative
enefit derived from this therapy, as illustrated in Figure 1
f their report, raises the question of whether therapy should
e started even earlier. If further follow-up demonstrates
educed mortality in the treatment group, consideration
hould be given to starting treatment at diagnosis.
Many questions regarding the role of dystrophin in
ardiomyopathy remain. For example, why does skeletal
uscle myopathy precede the onset of cardiomyopathy in
uchenne patients when skeletal muscles are used sporad-
cally while cardiac muscle works continuously? A major
echanism for development of cardiomyopathy in entero-
iral myocarditis appears to be cleavage of dystrophin by a
rotease produced by the virus (8). Why is this acute
leavage of dystrophin associated with rapid onset and
rogression of cardiomyopathy while chronic absence of
unctional dystrophin in Duchenne muscular dystrophy is
ssociated with onset of ventricular dysfunction only after a
ecade or more? Disruption of the dystrophin complex is
een in end-stage heart failure (9). Unloading the myocar-
ium with use of a ventricular assist device leads both to
egeneration of the dystrophin complex and, in some cases,
o improvement in ventricular function and symptoms of
eart failure (10). Is the dystrophin abnormality seen in
nd-stage heart failure the chicken or the egg? Is this really
art of the pathophysiology or an epiphenomenon?
Alternatively, another pathway unrelated to dystrophin
ay be active here. Uncoupling proteins (UCPs) are mito-
hondrial proton transporters that lower the electrochemical
radient favoring formation of adenosine triphosphate.
ncoupling protein-2 appears to be up-regulated in chronic
eart failure models (11), resulting in impaired myocardial
nergy efficiency. Chronic ischemic heart failure models
ave shown reduced creatine phosphate levels (12) despite
isproportionately high oxygen consumption (13), and this
an be reversed by ACE inhibitors (14). Studies in a rat
odel of chronic aortic regurgitation have shown that
erindopril reduces expression of uncoupling protein-2,
aintains normal levels of creatine phosphate, and prevents
ardiac remodeling (15). Perhaps the prevention, or at least
lowing of progression, of left ventricular dysfunction in this
rial is more related to prevention of energy wasting than to
revention of mechanical disruption of myocytes.
Answers to questions such as these are likely to enhance
ur understanding of the cellular mechanics of heart failure.
he skeletal and cardiac myopathies associated with abnor-
alities of the dystrophin complex, seen mostly in children,rovide models in which answers to these and other ques-
ions are likely to be found. But these answers will be found
nly with patience and by study groups with access to
ufficient patients.
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